Perampanel 4mg for Epilepsy

"Our team at Power judged the safety of perampanel one week titration to be a 3 due to this being classified as Phase 4, which is indicative of said treatment's approval."

"Per the trial sponsor, Eisai Inc., the primary outcome for this study is Overall Neuropsychological Composite Z-score as a measure of direct comparison across the titration conditions over 6 weeks. There are secondary outcomes being studied including overall cognitive and behavioral composite Z-scores at week 6 compared to baseline. These scores indicate how far away from average performance an individual patient is; 0 indicates average performance while negative numbers mean poorer performance than average and positive numbers signify better than typical results."

"Research into Perampanel 1 week titration began in 2017, with the initial trial sponsored by Eisai Inc. and involving 60 participants. This was followed by N/A drug approval and 11 currently active studies across 51 cities and 9 countries."

"Affirmative. According to records on clinicaltrials.gov, this medical study is currently enrolling patients; it was initially made available on October 20th 2021 and recently updated on the 25th of October 2022. 103 individuals from 3 different sites need to be recruited for participation in the trial."

"Affirmative. Information available on clinicaltrials.gov shows that this medical trial, which was initially published on October 20th 2021, is currently searching for participants. 103 individuals need to be enrolled from three separate sites."

"This medical experiment will be conducting research on 103 participants with aura, between the ages of 18 and 55 years old. In order to qualify for this study, potential patients should satisfy two conditions: Be a male or female adult who is in good health and utilizing an accepted form of birth control."

"To qualify for this trial, the age of participants must be within the range of 18 to 55 years old."

"Presently, 11 studies exploring Perampanel 1 week titration are in progress with none currently residing in Stage 3 of the research process. Most of these trials emanate from New york City but there are a total of 93 sites conducting this type of investigation."